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Summary
Background: Chylous ascites is rare, accounting for less than 1% of cases. An
appropriate and stepwise approach to its diagnosis and management is of key
importance.
Aim: To review the current diagnostic approach and management of chylous
ascites.
Methods: A literature search was conducted using PubMed using the key words
‘chylous’, ‘ascites’, ‘cirrhosis’, ‘pathophysiology’, ‘nutritional therapy’, ‘paracentesis”,
“transjugular intrahepatic portosystemic shunt” and “TIPSS’. Only articles in English
were included.
Results: Chylous ascites is caused by the traumatic or obstructive disruption of the
lymphatic system that leads to extravasation of thoracic or intestinal lymph into the
abdominal space and the accumulation of a milky fluid rich in triglycerides. The most
common causes are malignancy, cirrhosis and trauma after abdominal surgery. This
condition can lead to chyle depletion, which results in nutritional, immunologic and
metabolic deficiencies. An ascitic triglyceride concentration above 200 mg/dL is
consistent with chylous ascites. Treatment is based on management of the underly-
ing cause and nutritional support.
Conclusions: Chylous ascites is mostly due to malignancy and cirrhosis in adults,
and congenital lymphatic disorders in children. Treatment with nutritional optimiza-
tion and management of the underlying etiology are the cornerstones of therapy.
When conservative measures fail, other interventions such as octreotide/somato-
statin analogues, surgical ligation, embolization and transjugular intrahepatic por-
tosystemic shunt in patients with cirrhosis can be considered.
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1 | INTRODUCTION
Chylous ascites is defined as a milky appearing, triglyceride-rich
peritoneal fluid, characterised by the presence of thoracic or
intestinal lymph in the abdominal cavity.1 Abdominal malignancy,
cirrhosis, lymphatic disruption after abdominal surgery, and infec-
tions represent the leading causes in adults.2 In children, congenital
lymphatic abnormalities and trauma are considered the most com-
mon etiologies.3 Its incidence is not well established, however, pre-
vious data from Press et al published in 1984 indicates that it
accounts for 1 per 20 000 hospital admissions overall, since then
no further epidemiological studies have been performed, thus the
current incidence is not well known.4 Chylous ascites is rich in
nutrients and immunoglobulins, which become no longer biologically
available after accumulating in the peritoneum. This can lead to
dehydration, malnutrition, electrolyte imbalance and immunosup-
pression.5 Therefore, prompt diagnosis and treatment is warranted.
Herein, we review best practices for diagnosis and conservative
treatment as well as emerging therapeutic options for refractory
cases of chylous ascites.
2 | METHODS
A literature search was conducted using PubMed using the key
words ‘chylous’, ‘ascites’, ‘cirrhosis’, ‘pathophysiology’, ‘nutritional
therapy’, ‘paracentesis” and “TIPSS’. Only articles in English were
included.
2.1 | Pathophysiology
The underlying cause of chylous ascites is the disruption of lym-
phatic flow. An interconnected network moves lymph—a complex
mixture of proteins, lipids/chylomicra, and immune cells—from the
body to the thoracic duct where it empties into the venous circula-
tion at the union of the left internal jugular vein and the subclavian
vein. Lymph is propelled through its circuit by the active, intrinsic
contraction/relaxation of lymphatic vessels and passive, external
compressive forces (skeletal muscles, central venous pressure varia-
tions, respiratory movement and pulsations of adjacent arteries).6
Approximately half of the lymph originates in the intestine. After
hydrolysis and emulsification, fatty acids and monoglycerides are
converted into triglycerides, which are subsequently absorbed into
the lymphatic system as chylomicrons. Hence, the milky appearance
of the lymph is attributed to its high triglyceride and free fatty acid
content.
Browse et al7 proposed three pathophysiologic mechanisms by
which chylous ascites occurs (Table 1): acquired lymphatic disrup-
tion, fibrosis of the lymphatic system and congenital causes.
Acquired lymphatic disruption from surgery or trauma, leads to dila-
tion of the retroperitoneal lymphatics with subsequent drainage of
lymph into the abdomen through a lymphoperitoneal fistula. This
dilation of lymphatic vessels also occurs as a result of the increased
lymph production and elevated hepatic venous pressure seen in
patients with cirrhosis and constrictive pericarditis. Cardiac condi-
tions such as right heart failure and dilated cardiomyopathy lead to
an increased lymphatic pressure from disrupted lymphatic drainage,
thereby causing lymph stasis, lymphatic dilation and chylous ascites.
The caval and hepatic venous hypertension precipitates an increment
in the production of hepatic lymph.8 The second proposed mecha-
nism is lymph node fibrosis, most commonly due to malignancy caus-
ing lymph flow obstruction from the gut into the cysterna chyli,
resulting in leakage from the dilated subserosal lymphatics into the
peritoneum. The chronic effects of a persistently elevated lymphatic
pressure may lead to collagen deposition at the basement membrane
of the lymphatics, impairing the intestinal mucosal absorptive capac-
ity. This process can cause protein-losing enteropathy with malab-
sorption, chronic steatorrhea and malnutrition. Last, congenital
causes like congenital lymphangiectasia lead to exudation and leak-
age of lymph through a fistula into the peritoneal cavity due to the
absence of lymphatic valves.
2.2 | Etiologies
Multiple etiologies have been described as causes of chylous ascites.
Traditionally, the most common causes in western countries are
abdominal malignancy and cirrhosis, accounting for two-thirds of
atraumatic chylous ascites cases.4 In developing and eastern coun-
tries, infections, such as tuberculosis and filariasis, are responsible
for the majority of cases. However, Steinemann et al3 performed a
systematic review of 190 patients with chylous ascites where a total
of 41 different etiologies were identified. The most common cause
was lymphatic anomalies (32%), a condition more prevalent in the
paediatric population. Malignant diseases were the second most
TABLE 1 Chylous ascites etiologies, mechanisms and causes
Etiology Mechanism Causes
Acquired Thoracic duct
obstruction or
disruption
Trauma/surgery
Infections (TB, filariasis),
radiotherapy, autoimmune
(SLE, sarcoidosis)
Increased lymph
production
Cirrhosis
Cardiovascular disease
Fibrosis Invasion and disruption
of the normal lymph
flow
Lymphomas
Neuroendocrine tumors
Sarcomas
Leukaemia
Solid organ malignancies
Congenital Disrupted or dilated
lymphatic vessels
Lymphangiectasia Waldmann’s
disease
Yellow-nail syndrome
Klippel-Trenaunay syndrome
Lymphangioma
TB, tuberculosis, SLE, systemic lupus erythematous.
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frequent etiology (7%). Cirrhosis and mycobacterial infections were
identified in 11% and 10% of the cases respectively.
2.2.1 | Malignancy
Malignancy causes chylous ascites through the invasion and disrup-
tion of the normal lymph flow.7 The most common malignancies
reported to cause chylous ascites are lymphomas, neuroendocrine
tumors, sarcomas (Kaposi sarcoma) and leukemias (chronic lymphatic
leukemias) in order of prevalence.3 Among the group of the above-
mentioned malignancies, lymphoma accounts for at least one-third
of the cases3 Solid malignancies can also cause chylous ascites.9,10
2.2.2 | Cirrhosis
Only 0.5%–1% of all cases of cirrhosis-related ascites are chylous in
nature.8,11 Runyon et al12 analyzed a total of 901 ascites samples
where eleven were chylous ascites; 10 of them were found to be
secondary to cirrhosis and one due to malignancy. The underlying
etiology is unclear but may be related to excessive hepatic and gas-
trointestinal lymph flow (up to 20 L/day) secondary to portal hyper-
tension, leading to spontaneous rupture of the serosal lymphatic
channels. Although data is limited, transjugular intrahepatic portosys-
temic shunt has proven effective for cases of refractory chylous
ascites.13,14 The decompression of the portal vein has shown to
relieve lymphatic hypertension.15
2.2.3 | Infection
Mycobacterium tuberculosis and filariasis represent the most common
causes of chylous ascites in third world countries.3 Granulomatous
lymphadenitis is thought to be the central cause of lymphatic
obstruction and development of chylous ascites in M. tuberculosis
infection. It is important to also consider the diagnosis of tuberculo-
sis in patients with alcohol abuse and malnutrition due to their rela-
tive immunocompromised state. Among patients with HIV, chylous
ascites can occur in association with M. tuberculosis, Mycobacterium
avium Complex and Kaposi sarcoma as a complication of immune
reconstitution inflammatory syndrome.16,17 Filariasis, an infection
caused by the parasite Wuchereria bancrofti in third world countries,
causes a severe inflammatory reaction in the lymphatics that results
in lymphedema and chylous ascites.
2.2.4 | Congenital
The congenital causes of chylous ascites are more commonly seen in
the paediatric population. Steinemann et al found lymphangiectasia as
the most common cause of congenital anomaly in children (84%).3
Lymphangiectasia or Waldmann’s disease is characterised by the pres-
ence of dilated lymph vessels due to the lack of valves in the submu-
cosa of the small bowel resulting in leakage of lymph. Waldmann first
described this disorder in 1961 as a cause of protein-losing enteropa-
thy, lymphopenia, hypoalbuminemia and hypogammaglobulinemia.18
Lymphatic anomalies account for only 8% of atraumatic cases of
chylous ascites.3
Other lymphatic anomalies exist, but constitute a smaller per-
centage of cases of congenital chylous ascites. For example, yellow-
nail syndrome causes chylous ascites due to hypoplastic lymphatics
and consists of the triad of lymphedema, pleural effusion and/or
chylous ascites and yellow discoloration with nail dystrophy.19 The
Klippel–Trenaunay syndrome is an inherited autosomal dominant dis-
order that is characterised by capillary and lymphatic hypoplastic
malformations that causes chylous ascites and is associated with soft
tissue and bony hypertrophy.20-22 Lymphangiomas arise from
sequestration of lymphatic tissue, which fail to communicate with
the lymphatic system, and can reside in the neck, intestine, pancreas
or mesentery.23,24
2.2.5 | Inflammatory
Chylous ascites may occur due to radiotherapy, retroperitoneal fibro-
sis (Ormond’s disease), and autoimmune diseases like sarcoidosis,
Behcet’s disease, Henoch–Sch€onlein purpura and systemic lupus ery-
thematous.25,26 Radiation has the same pathophysiological mecha-
nism as retroperitoneal fibrosis; both cause fibrosis and obstruction
of the lymphatics in the small bowel and mesentery with the devel-
opment of chylous ascites.27-29 Sarcoidosis can produce chylous
ascites by producing intrathoracic nodal fibrosis and lymphatic
obstruction. Chylous ascites from systemic lupus erythematous is
more often seen in the elderly who have an insidious onset of dis-
ease, which is less commonly associated with the classic rheumato-
logic manifestations.30,31 It is proposed that the inflammation of the
lymphatic vessels causes an increase in the endoluminal pressure dis-
rupting permeability of the lymphatic walls and leading to extravasa-
tion of chyle.32-34
2.2.6 | Traumatic and post-operative
Any abdominal trauma that disrupts the lymphatic vessels can cause
chylous ascites.35 In children, battered child syndrome should be
excluded in the presence of chylous ascites, as it accounts for 10%
of cases in the paediatric population.36,37 Chylous ascites can occur
early (around 1 week) after abdominal surgery due to disruption of
the lymphatic vessels or late (weeks to months) due to adhesions or
extrinsic compression of lymphatic vessels. Chylous ascites has been
reported after many surgical procedures, including thoracic or
abdominal aneurysm repair, retroperitoneal lymphadenectomy cathe-
ter placement for peritoneal dialysis, inferior vena cava resection,
vagotomy, Nissen fundoplication, gastric bypass, pancreaticoduo-
denectomy and gynecological surgery. Liver and kidney transplants
have also been associated with post-operative chylous ascites.38-40
Yilmaz et al41 reported a post-operative incidence of chylous ascites
of 4.6% in a total of 516 liver transplant cases over a 9-year period.
Low albumin, the presence of ascites before transplantation, and the
use of LigaSure vessel sealing system instead of conventional suture
were recognised as risk factors for developing chylous ascites.
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2.2.7 | Other causes
Other less common causes include cardiac conditions, nephrotic syn-
drome, pancreatitis, coeliac sprue, Whipple’s disease and retractile
mesenteritis.42-47 Cardiac disease with increased right-venous pres-
sures can lead to increased hepatic lymph production; causing
impaired drainage, chyle stasis, lymphatic dilation and ultimately chy-
lous ascites.48-50 These include right heart failure, dilated cardiomy-
opathy and constrictive pericarditis. Chen et al,51 reported a case of
chylous ascites secondary to cardiac amyloidosis, where the con-
tributing factor was thought to be increased left subclavian venous
pressure. Both acute necrotizing pancreatitis and chronic pancreatitis
are associated with chylous ascites; the underlying mechanism
remains unknown but is thought to be due to direct compression of
lymphatic channels.52,53
2.3 | Evaluation and diagnosis
The clinical evaluation of a patient that presents with ascites should
start with a thorough history and physical examination. The detailed
history must include family history, recent trauma or surgery, travel,
social history, and past medical history, particularly looking for
malignancy, liver or renal disease. The most common presenting
symptoms in order of frequency are abdominal distension, abdominal
pain, diarrhoea, dysphagia and progressive peripheral oedema.3
Other features may include nausea, vomiting, early satiety, diarrhoea,
steatorrhea, malnutrition, oedema, fever and night sweats. Shortness
of breath, weight gain and increased abdominal girth due to
increased abdominal pressure may be present. Physical examination
may reveal cachexia, temporal wasting, evidence of pleural effusions
or ascites, abdominal masses and hernias, stigmata of chronic liver
disease, and lower extremity oedema.
2.3.1 | Laboratory findings
Obtaining laboratory parameters in the blood and ascites is central
in the diagnosis and evaluation of chylous ascites. Standard blood
tests are required and should include complete blood count, basic
metabolic panel, liver function tests, total protein, albumin, lactate
dehydrogenase (LDH), lipid panel, amylase and lipase. A paracentesis
is mandatory and is the diagnostic tool of choice in evaluating
patients with ascites (Figure 1). If the appearance of the ascites is
milky and chylous ascites is suspected, a triglyceride level should be
measured in the ascitic fluid. A triglyceride concentration above
Ascites
Paracentesis
Color
Dark
Biliary Infectious
Consistency:
Cell count:
Total protein:
Thick
>500 (lymphocytic predominance)
Between 2.5-7.0 g/dL
Between 110-200 IU/L
< 1.1 g/dL
> 100 mg/dL
Low (ascites/serum ratio < 1)
Chylous ascites Cirrhosis Tuberculosis
+ Culture Triglyceride >200
Opaque Straw
SAAG
SAAG:
Cholesterol:
LDH:
Glucose:
+ ADA
< 1.1 > 1.1
Bloody
RBC >50,000 mm3
Trauma
post-surgical
Hemorrhagic
pancreatitis
Malignancy Cytology
History
Amylase
> 1000 IU/L
F IGURE 1 Ascites workup and chylous ascites fluid characteristics. RBC, red blood cells; SAAG, serum to ascites albumin gradient;
LDH, lactate dehydrogenase; ADA, adenosine deaminase
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200 mg/dL supports the diagnosis of chylous ascites, while a level
less than 50 mg/dL excludes it.1,4 The macroscopic appearance of
chylous ascites is turbid and thick compared to the straw-colored,
transparent ascitic fluid seen in portal hypertension.54 Microscopic
examination of the fluid stained with Sudan III shows fat globules
and leucocytes with a lymphocytic predominance. Ascitic fluid should
be sent for cytology, cell count, Gram’s stain, culture, total protein
concentration, albumin, LDH, glucose, triglyceride and amylase.55 If
tuberculosis is suspected, tuberculosis smear, adenosine deaminase
and culture should be performed. Adenosine deaminase is a sensitive
(93%) and specific (94%) method to diagnose peritoneal tuberculosis,
but peritoneal biopsy is required in some cases. The diagnostic accu-
racy of adenosine deaminase is not influenced by different study
settings, adenosine deaminase cut-off or methodological quality.56
The total protein content ranges between 2.5 and 7.0 g/dL and will
vary according to the underlying etiology.12 Typically, hepatic cirrho-
sis is associated with a total protein concentration in the ascites of
less than 2.5 g/dL. In addition, the serum to ascites albumin gradient
can be used to identify the presence of portal hypertension in the
setting of liver-related disease.57 A serum to ascites albumin gradient
below 1.1 g/dL rules out portal hypertension and suggests other eti-
ologies. In patients with chylous ascites secondary to cirrhosis, the
serum to ascites albumin gradient is normally above 1.1 g/dL.58,59
Interestingly, CA-125 has been reported to be particularly elevated
in cirrhotic patients with chylous ascites (Figure 2).60
2.3.2 | Radiology
Radiological assessment also plays an important role in the evalua-
tion of chylous ascites. Lymphangiography is the gold standard
diagnostic tool in cases of lymphatic obstruction. Lymphangiography
and lymphoscintigraphy are useful in detecting abnormal retroperi-
toneal nodes, leakage, fistulization and patency of the thoracic duct.
These techniques are also effective for selecting patients for surgery
and assessing the effects of treatment.61,62 Computed tomography
(CT) and magnetic resonance imaging are not specific to chylous
ascites, however, they are useful in identifying intraabdominal
masses, fluid collections or lymph nodes. The CT density of chylous
ascites resembles that of water and is indistinguishable from urine,
bile, bowel secretions or simple ascites.63
2.4 | Treatment
The management of chylous ascites is a multifaceted process with
limited therapeutic options available. The cornerstone of therapy
revolves around correcting the underlying cause and applying con-
servative measures to improve patient comfort, reduce recurrence
and optimise outcomes. Treatment should be individualised and
adjusted for the severity of chylous ascites. Conservative measures
are centered on maintaining an optimum nutritional balance and
administering therapies in order to reduce the production and flow
of lymph (Table 2).
The key initial step in management of chylous ascites is to opti-
mise the patient’s nutritional status. Nutritional support includes a
high-protein, low fat diet supplemented with medium-chain triglyc-
erides.64 Medium-chain triglycerides are absorbed by the enterocytes
and transported as free fatty acids and glycerol directly into the liver
through the portal vein, sparing the lymphatic system. This is in con-
trast to long-chained triglycerides, which are converted to free fatty
acids and monoglycerides that are then transported as chylomicrons
Chylous Ascites
Confirm
Triglyceride >200 mg/dL
History Recent trauma or
surgery
Fever, recent
travel
Malignancy
>1.1 g/dl
<1.1 g/dl
SAAG
Congential
diseases
Autoimmune
diseases
Radiation
Culture,
ADA
Infectious causes
(TB, filariasis)
Imaging
Consider
postoperative
complications or
trauma
Stigmata of
chronic liver
disease
Peritoneal
causes*
Other causes Inflammatory
causes
Portal
hypertension
causes
(cirrhosis)
Cytology,
Imaging
Weight loss,
masses
F IGURE 2 Chylous ascites differential diagnosis algorithm. *Peritoneal causes: consider malignancy, inflammatory or infectious causes.
SAAG, serum to ascites albumin gradient; ADA, adenosine deaminase; TB, tuberculosis
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to the intestinal lymph ducts contributing to the overall lymphatic
pool. Capric, caprylic and lauric acid are medium-chain triglycerides
found in coconut oil, palm kernel oil, whole milk, butter and cheese.
Most oils and fats, including nuts, fish, meat, olive oil and avocado
contain long-chained triglycerides and should be avoided in chylous
ascites.65 Orlistat, a gastric and pancreatic lipase inhibitor, has shown
to reduce the triglyceride concentration in ascites and can be used
adjunctively to a low-fat diet with medium-chain triglycerides,
although data is limited.66
Somatostatin, or its synthetic analogue, octreotide, have been
used as well in the treatment of chylous ascites.67 The exact mecha-
nism of action of somatostatin or its analogue is not completely
understood. However, it has shown to decrease portal pressure by
inhibiting glucagon and other intestinal peptide-mediated splanchnic
vasodilatation. It also diminishes peristalsis, intestinal absorption of
fats, triglyceride concentration in the thoracic duct and attenuates
the lymph flow in the major channels.68 Somatostatin must be
administered intravenously due to its short half-life of 1-3 minutes.
Octreotide has a longer half-life of 2 hours and the advantage of
subcutaneous administration. This somatostatin analogue has suc-
cessfully been used in patients with chylous ascites secondary to
pancreatitis, malignancy, post-liver transplant, portal vein thrombosis
and idiopathic cases.69,70 Berzigotti et al,68 utilised it as a long-term
medication during 6 months in a patient with refractory chylous
ascites in the setting of cirrhosis with no relapses after discontinua-
tion. In addition to nutrition and somatostatin analogues, total par-
enteral nutrition (TPN) can be considered if other measures fail.
However, emerging data has found enteral nutrition with medium-
chain triglycerides superior to TPN.71 Recently, Pan et al72 in a ret-
rospective study of 58 patients with post-operative chylous ascites
evaluated the clinical effect of somatostatin, enteral medium-chain
triglycerides diet and TPN. The early initiation of somatostatin
demonstrated better outcomes than its delayed initiation; and the
use of enteral nutrition with medium-chain triglycerides was superior
to TPN. Historically, TPN has also shown to have associated adverse
effects, such as cholestasis, fatty liver and fungal infections, which
may preclude its use.
Therapeutic paracentesis may be performed to provide tempo-
rary symptomatic relief. Repetitive drainage should be avoided as it
can lead to electrolyte imbalance, malnutrition and infection.73
Intravascular volume and albumin replacement to prevent post-para-
centesis circulatory derangements is not necessary unless the patient
has underlying cirrhosis.
The management of cirrhosis-related chylous ascites involves a
stepwise management approach. Initially, treatment is centered on
the use of diuretics and nutritional optimization with a low sodium,
low fat, and high protein diet with medium-chain triglycerides. In
patients who are refractory to medical therapy and maintain normal
liver function, transjugular intrahepatic portosystemic shunt can be
considered to help reduce portal pressures, although the data is lim-
ited.13,74 Even though the effects of transjugular intrahepatic por-
tosystemic shunt on chylous ascites are still preliminary, it is
believed that portal decompression reduces the flow of lymph and
reduces the formation of chylous ascites.14 The recurrence of symp-
toms after shunt dysfunction supports this theory.13 Nonetheless,
the benefit of transjugular intrahepatic portosystemic shunt place-
ments should be weighed with its inherent risks.
A number of additional therapeutic strategies have been trialed
for refractory chylous ascites including glue embolization, spleno-
renal shunt, surgical ligation and embolization of disrupted lymphatic
channels, but the data is preliminary.75-77 Peritoneovenous shunting
was used in the past, however, it is rarely performed nowadays due
to its high morbidity from sepsis, electrolyte imbalance, disseminated
intravascular coagulopathy, small bowel obstruction and air
TABLE 2 Approach to therapy in chylous ascites
Treatment Indication Mechanism References
First treat underlying cause
Dietary adjustments:
1. Low-fat, high protein diet
2. Medium-chain triglycerides
3. Low-salt (particularly in cirrhosis)
All causes of chylous
ascites
Reduces production and flow of chyle 64,65
Therapeutic paracentesis Temporary symptomatic relief 73
Orlistata Reversibly inhibits gastric and pancreatic lipase,
reducing absorption of fats
66
Somatostatin/Ocreotidea Exact mechanism unknown. Believed to decrease portal
pressure and reduce intestinal fat absorption
67-70
Diuretics Cirrhosis and cardiac related
chylous ascites
Facilitate excretion of volume reducing ascites formation 64
Transjugular intrahepatic
portosystemic shunta
Refractory cirrhosis related
chylous ascites
Reduce portal pressure 13,14,74
Other therapies such as glue embolization, spleno-renal shunt, surgical ligation and embolization of disrupted lymphatic channels are not recommended
due to preliminary data. Peritoneovenous shunting is no longer used due to high morbidity from adverse effects.75,77,78
aThere is not sufficient data for these interventions.
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embolism.78 Despite the number of potential therapeutic options
available for chylous ascites, conservative treatment remains the
cornerstone of therapy in these patients until further data emerges.
3 | CONCLUSIONS
Chylous ascites is an uncommon disorder characterised by the pres-
ence of a milky-appearing, triglyceride-rich fluid in the peritoneum.
It is caused by the disruption of the lymphatic system with subse-
quent leakage of thoracic or intestinal lymph into the abdominal
cavity. The most common etiologies are malignancy and cirrhosis in
adults and congenital lymphatic disorders in children. Infectious
causes are more prevalent in developing countries. Other patholo-
gies associated with chylous ascites include pancreatitis, sarcoidosis,
autoimmune diseases, post-surgical complications and other heredi-
tary disorders. The diagnosis is still based on clinical history, para-
centesis and ascitic fluid analysis. Perhaps the most relevant topic
regarding chylous ascites is its treatment. Conservative treatment
with nutritional optimization and treating the underlying etiology
remains the cornerstone of therapy for chylous ascites. A high pro-
tein, low fat diet with medium-chain triglycerides has shown to be
beneficial. When conservative measures fail, other interventions
such as ocreotide/somatostatin analogues, surgical ligation,
embolization and transjugular intrahepatic portosystemic shunt in
cirrhotic patients can be considered. Further investigation on the
optimal therapeutic management for refractory cases of chylous
ascites is warranted.
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